Показано 0 из 0
Дата |
---|
17.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
0.82
|
0.82
|
0.88
|
0.88
|
|
|
45.10
|
3.00
|
|
|
0.75
|
0.6175
|
0.80
|
0.66
|
|
|
30 868.39
|
806.00
|
|
|
0.60
|
0.60
|
0.61
|
0.61
|
|
|
3 621.61
|
88.00
|
|
|
0.7475
|
0.7475
|
0.75
|
0.75
|
|
|
8 279.61
|
218.00
|
|
|
0.58
|
0.47
|
0.70
|
0.675
|
|
|
15 418.10
|
316.00
|
|
|
0.3913
|
0.3913
|
0.44
|
0.44
|
|
|
176.68
|
6.00
|
|
|
0.4489
|
0.4489
|
0.46
|
0.46
|
|
|
14 038.56
|
125.00
|
|
1.20
|
0.60
|
0.47
|
0.60
|
0.47
|
|
|
609.75
|
17.00
|
|
1.20
|
0.48
|
0.48
|
0.59
|
0.59
|
|
|
993.24
|
24.00
|
|
0.48
|
0.3525
|
0.3525
|
0.40
|
0.40
|
|
|
519.75
|
14.00
|
Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab.